跳转至内容
Merck
CN
  • [Clinical efficacy of fluconazole, tinidazole and clindamycin vs fluconazole, tinidazole and azithromycin in the treatment of mixed cervical-vaginal infections, included those caused by Mycoplasma and Chlamydia trachomatis].

[Clinical efficacy of fluconazole, tinidazole and clindamycin vs fluconazole, tinidazole and azithromycin in the treatment of mixed cervical-vaginal infections, included those caused by Mycoplasma and Chlamydia trachomatis].

Ginecologia y obstetricia de Mexico (2013-07-04)
Jesús Roberto Villagrana-Zesati, Fernando M Guerra-Infante, Irma Elena Sosa-González
摘要

In the United States 19 million people acquire a sexually transmitted disease every year. Sexually transmitted diseases impact in gynecological terms because they may cause sterility, infertility and ectopic pregnancy. To compare the effectiveness of two combinations of three oral antimicrobial drugs in the treatment of mixed cervical-vaginal infections, included those caused by Mycoplasma and Chlamydia trachomatis. Aclinical, random, comparative, double-blind study included 50 patients assisting to infectology consult with diagnosis of mixed cervical-vaginal infection. Patients were divided into two groups: Group A (n = 25): fluconazole 37.5 mg, tinidazole 500 mg and azithromycin 250 mg; group B (n = 25): fluconazole 37.5 mg, tinidazole 500 mg and clindamycin 312.5 mg. Patients of both groups received two tablets twice p.o. for one day. Cultures were performed to corroborate the diagnosis and then to demonstrate effectiveness of the schemes studied. For the analysis of the data we used measures of central tendency, dispersion and inferential statistics for comparison of proportions by c2 and Fisher's exact tests with a significance level of p < 0.05. All patient got clinical cure; however, regarding the microbiologic eradication a positive case was identified in group A, requiring rescue treatment. The compliance in both groups was of 100%. In both groups, statistical analysis did not show significant differences. Three patients in group A had mild adverse effects. Patients mean age was 33.4 +/- 5.3 years. Both treatments showed similar effectiveness against mixed cervical-vaginal infections. Microbiological efficacy was of 96% and 100% in group A and B, respectively, besides, scheme of group B was better tolerated.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
氟康唑, ≥98% (HPLC), powder
Sigma-Aldrich
克林霉素 盐酸盐, lincosamide antibiotic
Supelco
阿齐霉素, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
氟康唑, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
克林霉素 盐酸盐, Pharmaceutical Secondary Standard; Certified Reference Material
克林霉素 盐酸盐, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
阿齐霉素 二水合物, ≥98% (HPLC)
阿齐霉素 二水合物, European Pharmacopoeia (EP) Reference Standard
阿齐霉素 二水合物, European Pharmacopoeia (EP) Reference Standard
氟康唑, European Pharmacopoeia (EP) Reference Standard
氟康唑, European Pharmacopoeia (EP) Reference Standard
Supelco
替硝唑, VETRANAL®, analytical standard